A critical overview of the pharmacologic management of treatment-resistant depression

被引：43

作者：

Nierenberg, Andrew A. ^{[1
]}

Katz, Judith ^{[1
]}

Fava, Maurizio ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA

来源：

PSYCHIATRIC CLINICS OF NORTH AMERICA | 2007年 / 30卷 / 01期

关键词：

D O I：

10.1016/j.psc.2007.01.001

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Major depressive disorder is a frequent, serious disorder that usually responds partially to treatment and leaves many patients with treatment resistance. This article reviews and critically evaluates the evidence for the management of treatment-resistant depression and examines pharmacologic approaches to alleviate the suffering of patients who benefit insufficiently from initial treatment.

引用

页码：13 / +

页数：18

共 140 条

[41] Switching to reboxetine: An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine [J].

Fava, M ;

McGrath, PJ ;

Sheu, WP .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) :365-369

[42] A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness [J].

Fava, M ;

Thase, ME ;

DeBattista, C .

JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) :85-93

[43] A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report [J].

Fava, Maurizio ;

Rush, A. John ;

Wisniewski, Stephen R. ;

Nierenberg, Andrew A. ;

Alpert, Jonathan E. ;

McGrath, Patrick J. ;

Thase, Michael E. ;

Warden, Diane ;

Biggs, Melanie ;

Luther, James F. ;

Niederehe, George ;

Ritz, Louise ;

Trivedi, Madhukar H. .

AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (07) :1161-1172

[44]

FAWCETT J, 1991, J CLIN PSYCHOPHARM, V11, P127

[45]

Feiger A, 1996, J CLIN PSYCHIAT, V57, P53

[46] Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone [J].

Ferreri, M ;

Lavergne, F ;

Berlin, I ;

Payan, C ;

Puech, AJ .

ACTA PSYCHIATRICA SCANDINAVICA, 2001, 103 (01) :66-72

[47] Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series [J].

Findling, RL .

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1996, 6 (03) :165-175

[48] Mood stabilizer augmentation in apparently "unipolar" MDD:: predictors of response in the naturalistic French national EPIDEP study [J].

Hantouche, EG ;

Akiskal, HS ;

Lancrenon, S ;

Chatênt-Duchêne, L .

JOURNAL OF AFFECTIVE DISORDERS, 2005, 84 (2-3) :243-249

[49]

HOWLEY CJ, 2000, 39 ANN M AM COLL NEU

[50] An open study of triiodothyronine augmentation of selective serotonin Reuptake inhibitors in treatment-resistant major depressive disorder [J].

Iosifescu, DV ;

Nierenberg, AA ;

Mischoulon, D ;

Perlis, RH ;

Papakostas, GI ;

Ryan, JL ;

Alpert, JE ;

Fava, M .

JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (08) :1038-1042

← 1 2 3 4 5 6 7 8 9 10 →